Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Debt Rating Affirmed, Outlook Raised

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Ratings has affirmed its ratings on Agilent Technologies' debt and has revised its outlook to 'positive' from 'stable.'

The Chicago-based rating agency affirmed Agilent's Issuer Default Rating of 'BBB,' as well as a 'BBB' rating on the firm's senior unsecured revolving credit facility and its senior unsecured notes.

Fitch said that it raised its outlook on Agilent due to "greater confidence in Agilent's operating and financial profile. The company's increasing percentage of organic sales from the faster growing and more profitable Life Sciences and Chemical Analysis segments should drive higher and less uneven operating performance over time," Fitch said in a statement.

The agency also cited Agilent's recently completed $1.5 billion acquisition of Varian as a catalyst for greater revenues in its Life Sciences and Chemical Analysis segments.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.